Latest Articles
Metastatic Carcinomas at the Episiotomy Site: A Systematic Literature Review.
Background/Objectives: Rarely, primary (PriCs) or metastatic (metECs) carcinomas occur in the episiotomy site. Methods: A systematic literature review of metECs was carried out. We reviewed the PRISMA guidelines and the …
Published: Aug. 27, 2025, midnight
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer - CancerNetwork
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer CancerNetwork
Published: Aug. 26, 2025, 10:07 p.m.
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer - Targeted Oncology
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer Targeted Oncology
Published: Aug. 26, 2025, 6:30 p.m.
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer - Oncology Nursing News
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer Oncology Nursing News
Published: Aug. 26, 2025, 6:04 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced - PharmiWeb.com
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced PharmiWeb.com
Published: Aug. 26, 2025, 4:10 p.m.
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer - OncLive
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer OncLive
Published: Aug. 26, 2025, 3:01 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for - GlobeNewswire
Genmab Receives FDA Breakthrough Therapy Designation for GlobeNewswire
Published: Aug. 26, 2025, 12:06 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - Yahoo Finance
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Yahoo Finance
Published: Aug. 26, 2025, noon
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial - Nature
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial Nature
Published: Aug. 26, 2025, 11:43 a.m.
GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor - connectedtoindia.com
GSK expands cancer treatment options in India with launch of immunotherapy and PARP inhibitor connectedtoindia.com
Published: Aug. 26, 2025, 4:39 a.m.
Link copied to clipboard!